Advertisement

Asthma Treatment, Adherence, and Use of PROs

Asthma affects approximately 19.2 million U.S. adults and 5.5 million children aged younger than 18 years. Each year, asthma causes 10.5 million...

The Role of JAK Inhibitors for Treating Myelofibrosis

Myelofibrosis (MF) is categorized by progressive bone marrow fibrosis, inefficient hematopoiesis, and reduced survival, and the etiology of the condition is unknown....

Treatment Considerations and Recommendations for Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disease that affects approximately 300,00 U.S. individuals. It is a chronic, progressive, life-shortening disease that primarily...

PARP Inhibitors for the Treatment of Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic cancers, and the five-year survival rate is about 47.6%. Treatment course usually...
Advertisement